# AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

> **NCT07030595** · PHASE3 · COMPLETED · sponsor: **Alebund Pharmaceuticals** · enrollment: 474 (actual)

## Conditions studied

- ESRD (End Stage Renal Disease)
- Chronic Kidney Disease(CKD)
- Hyperphosphatemia
- Hyperphosphatemia in Chronic Kidney Disease
- Dialysis
- Chronic Kidney Disease, Receiving Dialysis

## Interventions

- **DRUG:** AP301
- **DRUG:** Sevelamer carbonate (Renvela®)
- **DRUG:** AP301 Low Dose

## Key facts

- **NCT ID:** NCT07030595
- **Lead sponsor:** Alebund Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-12
- **Primary completion:** 2024-10-02
- **Final completion:** 2025-05-30
- **Target enrollment:** 474 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030595, "AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07030595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*